COMPASS Pathways plc (CMPS): R&D Expense
$118.44M
Year ended 2025-12-31
$112.89M
Trailing 12 months to 2026-06-30
+22.1%
3-year compound annual growth
+38.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $118.44M | -0.5% | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | $119.04M | +36.0% | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | $87.52M | +34.5% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $65.05M | +47.8% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $44.03M | +88.4% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $23.37M | +86.0% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $12.56M | n/a | 2022-02-24, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $118.44M | -0.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $62.07M | +13.0% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $19.96M | +62.1% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $26.81M | -22.0% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $67.11M | +17.4% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $109.16M | -35.5% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $9.58M | +4.4% |
Compare CMPS, PBYI, SIGA, ABEO side by side · Screen every company in Pharmaceutical Preparations ↗